Nanobiotix (NASDAQ:NBTX) Stock Price Up 1.1% – Here’s What Happened

Nanobiotix S.A. (NASDAQ:NBTX) shot up 1.1% during trading on Tuesday . The stock traded as high as $4.17 and last traded at $4.15. 1,204 shares changed hands during mid-day trading, a decline of 92% from the average session volume of 15,564 shares. The stock had previously closed at $4.10.

Wall Street Analyst Weigh In

NBTX has been the subject of a number of analyst reports. Guggenheim decreased their price target on Nanobiotix from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, April 4th. UBS Group upgraded Nanobiotix to a “hold” rating in a research note on Monday, February 17th.

Nanobiotix Trading Up 1.1%

The company has a 50-day moving average of $3.51 and a 200-day moving average of $3.42.

Institutional Investors Weigh In On Nanobiotix

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC bought a new position in shares of Nanobiotix during the 4th quarter worth about $29,000. Millennium Management LLC acquired a new position in shares of Nanobiotix during the fourth quarter worth approximately $39,000. Jane Street Group LLC acquired a new stake in Nanobiotix in the 4th quarter valued at $73,000. Finally, OLD Mission Capital LLC bought a new stake in Nanobiotix during the 4th quarter valued at $139,000. 38.81% of the stock is currently owned by institutional investors.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.